Details of the Drug Reposition

General Information of This Drug (ID: DMX6RZG)

Drug Name
EFT508   DMX6RZG
Synonyms
Tomivosertib; eFT508; 1849590-01-7; EFT-508; UNII-U2H19X4WBV; U2H19X4WBV; Tomivosertib [INN]; Tomivosertib [USAN]; SCHEMBL17362622; GTPL10167; eFT-508 (eFT508); EFT 508; MolPort-044-560-418; BCP18993; EX-A2494; ZINC575623807; AKOS030627405; CS-5841; compound 23 [PMID: 29526098]; HY-100022; S8275; 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-1'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'(2'H)-dione; 6-[(6-aminopyrimidin-4-yl)amino]-8-methylspiro[2H-imidazo[1,5-a]pyridine-3,1'-cyclohexane]-1,5-dione
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Colorectal cancer DISNH7P9 2B91.Z Phase 2 [1]
Hepatocellular carcinoma DIS0J828 2C12.02 Phase 2 [1]
Triple negative breast cancer DISAMG6N 2C60-2C65 Phase 2 [1]
------------------------------------------------------------------------------------
2 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [1]
Lymphoma DISN6V4S 2A80-2A86 Phase 1/2 [1]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)